Baxter Reports First-Quarter 2024 Results

First-quarter sales from continuing operations of $3.59 billion increased 2% on a reported basis and 3% on a constant currency basis, exceeding the company’s previously issued...

Related Keywords

Taiwan ,United States ,Ukraine ,Red Sea ,Djibouti General ,Djibouti ,China ,Joee Almeida , ,European Union ,Department Of Justice ,European Medicines Agency ,Biopharma Solutions ,Drug Administration ,Linkedin ,Dose Iq Safety Software ,Baxter Biopharma Solutions ,Baxter International Inc ,Connectivity Solutions ,Foreign Exchange ,Mission To Save ,Facebook ,Baxter International ,Drug Compounding ,Medical Products ,Kidney Care ,Healthcare Systems ,Integrated Supply ,Connectivity Suite ,Dextrose Injection ,Sodium Chloride Injection ,Hydrochloride Injection ,Investor Relations ,Regulations K ,Middle East ,Attorney General ,Accepted Accounting Principles ,Months Ended March ,Continuing Operations Before Income ,Chronic Therapies ,Acute Therapies ,Segment Net ,Segment Sales ,Cash Flow ,Free Cash ,Total Baxter ,Net Sales Growth As Reported ,Constant Currency Sales ,Three Months Ended March ,Second Quarter ,Full Year ,Projected Constant Currency Sales Growth ,Projected Second Quarter ,Earnings Per ,Markets ,